Creative Medical Technology Holdings (CELZ) Tax Provisions (2018 - 2025)
Creative Medical Technology Holdings (CELZ) posted quarterly Tax Provisions of $342374.0 for Q4 2025, down 69.51% year-over-year from $1.1 million in Q4 2024, and down 69.51% quarter-over-quarter from $1.1 million in Q4 2024.
Creative Medical Technology Holdings (CELZ) Tax Provisions (2018 - 2025) Analysis & Trends
Creative Medical Technology Holdings (CELZ) has reported Tax Provisions for 4 consecutive years, with $342374.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Tax Provisions fell 69.51% year-over-year to $342374.0; the TTM figure through Mar 2026 stood at $342374.0 (down 69.51% YoY), while the FY2025 annual figure was $342374.0, down 69.51% from the prior year.
- Tax Provisions declined to $342374.0 in Q4 2025 per CELZ's latest filing, from $1.1 million in the prior quarter.
- Across five years, Tax Provisions topped out at $1.1 million in Q4 2024 and bottomed at $342374.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.78 Bn | 131.93 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 86.58 Bn | 78.59 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 65.29 Bn | 60.11 Bn | 1.37 Bn | 59.00 Mn |
| 4 | Moderna | 58.86 Bn | 53.73 Bn | 52.00 Mn | 15.00 Mn |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn | 75.45 Mn |
| 6 | Alnylam Pharmaceuticals | 31.73 Bn | 28.42 Bn | 992.69 Mn | 13.31 Mn |
| 7 | BioNTech SE | 28.19 Bn | 9.80 Bn | 668.28 Mn | -90.33 Mn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 1.90 Mn |
| 9 | Royalty Pharma | 27.24 Bn | 26.41 Bn | - | - |
| 10 | Creative Medical Technology Holdings | 1.84 Mn | 1.84 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 342,374.00 |
| Dec 31, 2024 | 1.12 Mn |
| Dec 31, 2020 | 69,671.00 |
| Dec 31, 2018 | -234,666.00 |